REG - Oxford Biomedica PLC - Result of AGM

Oxford BioMedicaAnnouncement

29/05/2019 13:10

RNS Number : 4975A
Oxford Biomedica PLC
29 May 2019
 


 
 
 
Oxford Biomedica
Result of Annual General Meeting
 
Oxford, UK - 29 May 2019: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London. 
 
In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:
 
·      Resolution 12: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;
·      Resolution 13: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and
·      Resolution 14: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.
 
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com
 
Certified copies of the document setting out the above resolutions passed at the 2019 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM
 
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (24 May 2019) there were 68,928,847 ordinary shares in issue, each carrying one vote per share.
 



 
 
Resolution


 
Votes
For


Votes at
Chairman's
Discretion


Votes at
other proxy
Discretion


 
Votes
Against


 
Votes
Withheld*


 
Total
votes cast


Result






































Ordinary resolutions


























































1


26,128,255


74


9,660


1,440


45,237


26,139,429


Passed






































2


24,809,196


74


9,660


1,365,178


557


26,184,108


Passed






































3


25,883,062


74


9,660


285,720


6,150


26,178,516


Passed




4


 
26,046,456


 
74


 
9,660


 
121,237


 
7,239


 
26,177,427


 
Passed






































5


26,046,389


74


9,660


121,304


7,239


26,177,427


Passed






































6


26,060,761


74


9,660


108,021


6,150


26,178,516


Passed






































7


24,938,310


74


9,660


887,698


348,924


25,835,742


Passed






































8


26,059,432


74


9,660


108,261


7,239


26,177,427


Passed






































9


26,060,787


74


9,660


107,995


6,150


26,178,516


Passed






































10


26,171,417


74


9,660


2,650


865


26,183,801


Passed






































11


25,425,808


74


9,660


649,226


99,898


26,084,768


Passed






































 
Special resolutions


























































12


25,737,271


74


9,660


338,597


99,064


26,085,602


Passed






































13


25,737,113


74


9,660


338,729


99,090


26,085,576


Passed






































14


25,554,287


74


9,660


620,379


266


26,184,400


Passed





































 
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
 
 
-Ends-
 
 



Enquiries:


 




 
Oxford Biomedica plc
 
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development & IR
Sarah MacLeod, Head of Communications
 


 
 
 
T: +44 (0)1865 783 000
T: +44 (0)1865 783 000
T: +44 (0)1865 954 161 / E: ir@oxb.com
T: +44 (0)7747 602 739 / E: media@oxb.com




Consilium Strategic Communications
 
Mary-Jane Elliott/Matthew Neal


 
 
T: +44 (0)20 3709 5700



 
 
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEIFEUFUSESI